Celldex Therapeutics
CLDX
164 hedge funds and large institutions have $2.42B invested in Celldex Therapeutics in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 60 increasing their positions, 45 reducing their positions, and 12 closing their positions.
175% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
74% more capital invested
Capital invested by funds: $1.39B → $2.42B (+$1.03B)
33% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 45
14% more funds holding
Funds holding: 144 → 164 (+20)
4.51% more ownership
Funds ownership: 107.01% → 111.52% (+4.5%)
29% less call options, than puts
Call options by funds: $20.5M | Put options by funds: $28.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$59.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$41.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$21.8M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$18.9M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$5.71M |
| 3 |
Millennium Management
New York
|
-$4.33M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.26M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.56M |
CLDX Hedge Fund Activity: Q4 2023 in Review
164 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2023, worth a combined $2.42B — up 74% from $1.39B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CLDX positions and 12 closed out — a net gain of 21 holders — while 60 added to existing stakes and 45 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $59.7M. The largest seller was Redmile Group, cutting an estimated $18.9M.
- 164 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2023, up from 144 in Q3 2023.
- Funds reported $2.42B of Celldex Therapeutics stock for Q4 2023, up 74% quarter-over-quarter.
- 33 funds opened new Celldex Therapeutics positions in Q4 2023 and 12 closed out, a net change of +21 holders.
- The largest Celldex Therapeutics buyer in Q4 2023 was Eventide Asset Management, an estimated $59.7M added.
- The largest Celldex Therapeutics seller in Q4 2023 was Redmile Group, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2023.